% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Sahm:276718,
      author       = {F. Sahm$^*$ and S. Brandner and L. Bertero and D.
                      Capper$^*$ and P. J. French and D. Figarella-Branger and F.
                      Giangaspero and C. Haberler and M. E. Hegi and B. W.
                      Kristensen and K. M. Kurian and M. Preusser and B. B. J.
                      Tops and M. van den Bent and W. Wick$^*$ and G.
                      Reifenberger$^*$ and P. Wesseling},
      title        = {{M}olecular diagnostic tools for the {W}orld {H}ealth
                      {O}rganization ({WHO}) 2021 classification of gliomas,
                      glioneuronal and neuronal tumors; an {EANO} guideline.},
      journal      = {Neuro-Oncology},
      volume       = {25},
      number       = {10},
      issn         = {1522-8517},
      address      = {Oxford},
      publisher    = {Oxford Univ. Press},
      reportid     = {DKFZ-2023-01111},
      pages        = {1731-1749},
      year         = {2023},
      note         = {#EA:B300# / 2023 Oct 3;25(10):1731-1749},
      abstract     = {In the 5th edition of the WHO CNS tumor classification
                      (CNS5, 2021), multiple molecular characteristics became
                      essential diagnostic criteria for many additional CNS tumor
                      types. For those tumors, an integrated, 'histomolecular'
                      diagnosis is required. A variety of approaches exists for
                      determining the status of the underyling molecular markers.
                      The present guideline focuses on the methods that can be
                      used for assessment of the currently most informative
                      diagnostic and prognostic molecular markers for the
                      diagnosis of gliomas, glioneuronal and neuronal tumors. The
                      main characteristics of the molecular methods are
                      systematically discussed, followed by recommendations and
                      information on available evidence levels for diagnostic
                      measures. The recommendations cover DNA and RNA
                      next-generation-sequencing, methylome profiling, and select
                      assays for single/limited target analysis, including
                      immunohistochemistry. Additionally, because of its
                      importance as a predictive marker in IDH-wildtype
                      glioblastomas, tools for the analysis of MGMT promoter
                      status are covered. A structured overview of the different
                      assays with their characteristics, especially their
                      advantages and limitations, is provided, and requirements
                      for input material and reporting of results are clarified.
                      General aspects of molecular diagnostic testing regarding
                      clinical relevance, accessibility, cost, implementation,
                      regulatory and ethical aspects are discussed as well.
                      Finally, we provide an outlook on new developments in the
                      landscape of molecular testing technologies in
                      neuro-oncology.},
      keywords     = {WHO classification (Other) / glioma (Other) / glioneuronal
                      tumors (Other) / molecular classification (Other) / neuronal
                      tumors (Other)},
      cin          = {B300 / HD01 / B320 / BE01 / ED01},
      ddc          = {610},
      cid          = {I:(DE-He78)B300-20160331 / I:(DE-He78)HD01-20160331 /
                      I:(DE-He78)B320-20160331 / I:(DE-He78)BE01-20160331 /
                      I:(DE-He78)ED01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:37279174},
      doi          = {10.1093/neuonc/noad100},
      url          = {https://inrepo02.dkfz.de/record/276718},
}